002907.SHE Chongqing Pharscin Pharmaceutical Co Ltd
- Market cap
- CNY 5.39B
- P/E
- 56.1x
- P/B
- 3.13x
- ROE
- 7.7%
- Dividend yield
- 0.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002907.SHE undervalued?
Graham number002907.SHE trades 179.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Pharscin Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Chongqing Pharscin Pharmaceutical Co Ltd yet.
Chongqing Pharscin Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical raw materials, and traditional Chinese medici…
Full company profileChongqing Pharscin Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Pharscin Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 552M | 592M | 703M | 842M | 882M | 846M | 785M | 692M | 775M | 827M | 865M |
| Gross Profit | 355M | 397M | 472M | 535M | 424M | 446M | 465M | 379M | 442M | 475M | 488M |
| Operating Income | 93.6M | 131M | 158M | 198M | 137M | 103M | 109M | 45.8M | 93.8M | 69.6M | 140M |
| EBITDA | 135M | 154M | 184M | 231M | 201M | 191M | 197M | 126M | 178M | 166M | 155M |
| Net Income | 95.7M | 112M | 137M | 170M | 119M | 91.8M | 98.4M | 32.7M | 76.7M | 65.1M | 135M |
| EPS | 0.27 | 0.31 | 0.34 | 0.42 | 0.30 | 0.23 | 0.24 | 0.08 | 0.18 | 0.16 | 0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 652M | 885M | 1.09B | 1.64B | 1.72B | 1.77B | 1.87B | 1.85B | 1.92B | 2.03B | 2.05B |
| Total Liabilities | 191M | 165M | 265M | 567M | 540M | 506M | 256M | 234M | 258M | 320M | 278M |
| Shareholders' Equity | 461M | 720M | 829M | 1.07B | 1.18B | 1.27B | 1.61B | 1.62B | 1.66B | 1.69B | 1.76B |
| Cash & Short-term Investments | 85.2M | 243M | 243M | 480M | 531M | 511M | 504M | 438M | 577M | 274M | 344M |
| Total Debt | 45.0M | 17.0M | 48.7M | 220M | 247M | 251M | 170K | 140K | 128K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.7M | 81.3M | 31.8M | 65.9M | 114M | 82.9M | 13.0M | 219M | 162M | 62.2M | - |
| Capital Expenditure | 16.7M | 41.9M | 36.3M | 64.7M | 46.7M | 56.6M | 60.6M | 92.8M | 16.2M | 14.6M | 40.1M |
| Free Cash Flow | 41.0M | 39.5M | -4.50M | 1.25M | 66.9M | 26.2M | -47.6M | 127M | 146M | 47.7M | 68.9M |
| Ratios | |||||||||||
| ROE | 20.7% | 15.6% | 16.6% | 15.9% | 10.1% | 7.3% | 6.1% | 2.0% | 4.6% | 3.8% | 7.7% |
| ROA | 14.7% | 12.7% | 12.6% | 10.4% | 6.9% | 5.2% | 5.3% | 1.8% | 4.0% | 3.2% | 6.6% |
| Net Profit Margin | 17.3% | 18.9% | 19.5% | 20.2% | 13.5% | 10.8% | 12.5% | 4.7% | 9.9% | 7.9% | 15.6% |
| Debt to Equity | 0.10x | 0.02x | 0.06x | 0.21x | 0.21x | 0.20x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chongqing Pharscin Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.66%
- Forward dividend
- 0.08 CNY
- Payout ratio
- 54.5%
- Ex-dividend date
- Sep 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 35.5M | 0.08 | 54.5% |
| 2024 | CNY 35.5M | 0.08 | 46.3% |
| 2023 | CNY 30.2M | 0.07 | 92.3% |
| 2022 | CNY 20.0M | 0.05 | 20.3% |
| 2021 | CNY 13.4M | 0.03 | 14.6% |
| 2020 | CNY 19.4M | 0.05 | 16.3% |
| 2019 | CNY 14.8M | 0.04 | 8.7% |
| 2018 | CNY 29.6M | 0.07 | 21.6% |
| 2017 | CNY 1.10M | 0.00 | 1.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Chongqing Pharscin Pharmaceutical Co Ltd
- Insiders 70.76%
- Institutions 2.06%
- Public & others 27.18%
- Shares outstanding 418M
- Free float 126M
Chongqing Pharscin Pharmaceutical Co Ltd company profile
- Company name
- Chongqing Pharscin Pharmaceutical Co Ltd
- Ticker
- 002907.SHE
- ISIN
- CNE100003308
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,439
- Fiscal year end
- December
- Address
- No. 89, Middle Section of Huangshan Avenue, Chongqing, China, 401120
- Phone
- 86 29 6762 2999
- Website
- pharscin.com
About Chongqing Pharscin Pharmaceutical Co Ltd
Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical raw materials, and traditional Chinese medicine extracts. The company is also involved in the provision of CDMO and CMO services; pharmaceutical technology development services and consulting; wholesale and retail activities; and scientific research and technical services. Its products are used in digestive diseases, central nervous system disorders, and otolaryngology therapeutic areas. The company was incorporated in 1996 and is headquartered in Chongqing, China.
Chongqing Pharscin Pharmaceutical Co Ltd management
9- Mr. Hongtao YouChairman & GM · born 1962
- Ms. Xiaoyan PengAccounting Supervisor & CFO · born 1975
- Ms. You YuanyiDeputy GM & Director · born 1994
- Ms. Xue Dan YouDeputy GM, Secretary of the Board & Non-Independent Director · born 1988
- Ms. Ying WangDeputy General Manager · born 1962
- Mr. Jie HuangDeputy General Manager · born 1974
- Mr. Yong Lu HangCOO & Deputy GM · born 1948
- Mr. Lie Chun ChenChief Technology Officer · born 1963
- Ge LeiSecurities Affairs Representative